BRISBANE, Calif. - CareDx, Inc. (NASDAQ:CDNA), a company specializing in precision medicine for transplant patients, announced today the appointment of Bryan Riggsbee to its Board of Directors, effective immediately. Riggsbee, who brings extensive financial and operational experience to the role, will serve as Chair of the Audit and Finance Committee.
Riggsbee's career includes significant roles in finance, notably as Chief Financial Officer at Myriad Genetics (NASDAQ:MYGN) and a decade-long tenure at Laboratory Corporation of America (NYSE:LH). His expertise extends to his time with General Electric Company (NYSE:GE) and his beginnings in the audit division of KPMG.
As a Certified Public Accountant in North Carolina, Riggsbee's background is expected to contribute to CareDx's financial and strategic development.
"Bryan's financial expertise and understanding of revenue cycle management in molecular diagnostics will allow him to make meaningful contributions to our Board," said Michael Goldberg, CareDx Board Chairperson.
The new board member expressed enthusiasm about his appointment, stating, "I am thrilled to join the CareDx Board, an innovator and leader in the field of organ transplantation. I look forward to working with the company's leadership team to advance its mission of improving long-term outcomes by delivering innovative solutions across the entire transplant patient journey."
Riggsbee succeeds George Bickerstaff, who will continue to serve on the Audit and Finance Committee, indicating a smooth transition in the company's leadership structure.
CareDx, based in Brisbane, California, is recognized for providing a range of testing services, products, and digital healthcare solutions designed to support transplant patients before and after their procedures. The company emphasizes its commitment to delivering genomics-based information that can enhance patient care.
This announcement is based on a press release statement from CareDx, Inc. and is intended to inform stakeholders and the public of the latest developments within the company's governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.